Literature DB >> 18684127

Altered pharmacology in the Intensive Care Unit patient.

Giovanni Zagli1, Francesca Tarantini, Manuela Bonizzoli, Alessandro Di Filippo, Adriano Peris, Angelo Raffaele De Gaudio, Pierangelo Geppetti.   

Abstract

Critically ill patients, not infrequently present alterations of physiological parameters that determine the success/failure of therapeutic interventions as well as the final outcome. Sepsis and polytrauma are two of the most common and complex syndromes occurring in Intensive Care Unit (ICU) and affect drug absorption, disposition, metabolism and elimination. Pharmacological management of ICU patients requires consideration of the unique pharmacokinetics associated with these clinical conditions and the likely occurrence of drug interaction. Rational adjustment in drug choice and dosing contributes to the appropriateness of treatment of those patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18684127     DOI: 10.1111/j.1472-8206.2008.00623.x

Source DB:  PubMed          Journal:  Fundam Clin Pharmacol        ISSN: 0767-3981            Impact factor:   2.748


  10 in total

1.  Ceftazidime dosage regimen in intensive care unit patients: from a population pharmacokinetic approach to clinical practice via Monte Carlo simulations.

Authors:  Bernard Georges; Jean-Marie Conil; Stéphanie Ruiz; Thierry Seguin; Pierre Cougot; Olivier Fourcade; Georges Houin; Sylvie Saivin
Journal:  Br J Clin Pharmacol       Date:  2012-04       Impact factor: 4.335

2.  A Prospective Analysis of Drug Interactions in Patients of Intensive Cardiac Care Unit.

Authors:  Shipra Jain; Pushpawati Jain; Kopal Sharma; Pushpendra Saraswat
Journal:  J Clin Diagn Res       Date:  2017-03-01

3.  Inferior vena cava filters for primary prophylaxis: when are they indicated?

Authors:  Eric Wehrenberg-Klee; S William Stavropoulos
Journal:  Semin Intervent Radiol       Date:  2012-03       Impact factor: 1.513

4.  Short acting insulin analogues in intensive care unit patients.

Authors:  Federico Bilotta; Carolina Guerra; Rafael Badenes; Simona Lolli; Giovanni Rosa
Journal:  World J Diabetes       Date:  2014-06-15

5.  Approach to the patient with transient alteration of consciousness.

Authors:  Thomas R Henry; Mustapha A Ezzeddine
Journal:  Neurol Clin Pract       Date:  2012-09

6.  Prevalence of potential drug interactions in patients in an intensive care unit of a university hospital in Brazil.

Authors:  Adriano Max Moreira Reis; Silvia Helena De Bortoli Cassiani
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

7.  Population pharmacokinetics of dexmedetomidine in critically ill patients.

Authors:  Pyry Antti Välitalo; Tuula Ahtola-Sätilä; Andrew Wighton; Toni Sarapohja; Pasi Pohjanjousi; Chris Garratt
Journal:  Clin Drug Investig       Date:  2013-08       Impact factor: 2.859

8.  Biocompatible N-acetyl-nanoconstruct alleviates lipopolysaccharide-induced acute lung injury in vivo.

Authors:  Seongchan Kim; Shin Young Kim; Seung Joon Rho; Seung Hoon Kim; So Hyang Song; Chi Hong Kim; Hyojin Lee; Sung Kyoung Kim
Journal:  Sci Rep       Date:  2021-11-22       Impact factor: 4.379

9.  Prolonged lipopolysaccharide-induced illness elevates glucagon-like peptide-1 and suppresses peptide YY: A human-randomized cross-over trial.

Authors:  Katrine Brodersen; Maike Mose; Ulla Ramer Mikkelsen; Jens Otto Lunde Jørgensen; Michael Festersen Nielsen; Niels Møller; Anne-Marie Wegeberg; Christina Brock; Bolette Hartmann; Jens Juul Holst; Nikolaj Rittig
Journal:  Physiol Rep       Date:  2022-09

10.  Important drug classes associated with potential drug-drug interactions in critically ill patients: highlights for cardiothoracic intensivists.

Authors:  Shadi Baniasadi; Behrooz Farzanegan; Maryam Alehashem
Journal:  Ann Intensive Care       Date:  2015-11-24       Impact factor: 6.925

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.